Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity

By afschroeder • August 6, 2025

Tsaktanis T, Ammon L, Lößlein L, Peter A, Vandrey O, Naumann UJ, Behne M, Cook LJ, Levy M, Yeaman MR, Bennett JL, Rothhammer V; Guthy-Jackson Charitable Foundation CIRCLES Study Group. Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200457. doi: 10.1212/NXI.0000000000200457. Epub 2025 Aug 5. PMID: 40763318.

Tags: Harbor UCLA, Infectious Diseases, Publications

Cefadroxil as Oral Transitional Therapy for Gram-Positive Bacteremia With or Without Non-Vertebral Osteomyelitis: A Multicenter Retrospective Cohort Study

Clark DC, Baden R, Banerjee J, Bedrossian R, Chute H, Davar K, Deng D, Donnelly M, Fernandez D, Goodman R, Gordon H, Harris E, Hutcheon[...]

Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD

Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, Kovesdy CP. Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with[...]

A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023

Maverakis Ramirez N, Jaeger ZJ, Lee DJ. A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023. Cureus. 2026 Jul 8;18(7):e112280.[...]